JP2020518266A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518266A5
JP2020518266A5 JP2019560388A JP2019560388A JP2020518266A5 JP 2020518266 A5 JP2020518266 A5 JP 2020518266A5 JP 2019560388 A JP2019560388 A JP 2019560388A JP 2019560388 A JP2019560388 A JP 2019560388A JP 2020518266 A5 JP2020518266 A5 JP 2020518266A5
Authority
JP
Japan
Prior art keywords
sequence
region
strand sequence
antisense strand
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019560388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518266A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031108 external-priority patent/WO2018204797A1/en
Publication of JP2020518266A publication Critical patent/JP2020518266A/ja
Publication of JP2020518266A5 publication Critical patent/JP2020518266A5/ja
Priority to JP2023075746A priority Critical patent/JP7768928B2/ja
Pending legal-status Critical Current

Links

JP2019560388A 2017-05-05 2018-05-04 調節性ポリヌクレオチド Pending JP2020518266A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023075746A JP7768928B2 (ja) 2017-05-05 2023-05-01 調節性ポリヌクレオチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762501787P 2017-05-05 2017-05-05
US62/501,787 2017-05-05
US201762507923P 2017-05-18 2017-05-18
US62/507,923 2017-05-18
US201762520093P 2017-06-15 2017-06-15
US62/520,093 2017-06-15
PCT/US2018/031108 WO2018204797A1 (en) 2017-05-05 2018-05-04 Modulatory polynucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023075746A Division JP7768928B2 (ja) 2017-05-05 2023-05-01 調節性ポリヌクレオチド

Publications (2)

Publication Number Publication Date
JP2020518266A JP2020518266A (ja) 2020-06-25
JP2020518266A5 true JP2020518266A5 (enExample) 2021-07-26

Family

ID=64016722

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560388A Pending JP2020518266A (ja) 2017-05-05 2018-05-04 調節性ポリヌクレオチド
JP2023075746A Active JP7768928B2 (ja) 2017-05-05 2023-05-01 調節性ポリヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023075746A Active JP7768928B2 (ja) 2017-05-05 2023-05-01 調節性ポリヌクレオチド

Country Status (9)

Country Link
US (2) US20200270635A1 (enExample)
EP (1) EP3619310A4 (enExample)
JP (2) JP2020518266A (enExample)
CN (2) CN118910166A (enExample)
AU (1) AU2018260998B2 (enExample)
CA (1) CA3061365A1 (enExample)
SG (1) SG11201909777YA (enExample)
TW (1) TWI897844B (enExample)
WO (1) WO2018204797A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
KR102584655B1 (ko) 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
AU2017268382B2 (en) 2016-05-18 2023-09-28 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
WO2019241486A1 (en) 2018-06-13 2019-12-19 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
AU2019299861A1 (en) * 2018-07-02 2021-01-14 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
WO2020023612A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
EP3861113A1 (en) 2018-10-04 2021-08-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
EP3861107A1 (en) 2018-10-05 2021-08-11 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
JP2022505106A (ja) 2018-10-15 2022-01-14 ボイジャー セラピューティクス インコーポレイテッド バキュロウイルス/Sf9システムにおけるrAAVの大規模産生のための発現ベクター
CN113631225A (zh) 2019-01-18 2021-11-09 沃雅戈治疗公司 用于生产aav颗粒的方法和系统
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
WO2020223280A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CN111450083A (zh) * 2020-04-28 2020-07-28 天津大学 一种肝癌靶向治疗纳米颗粒的合成方法
GB202010981D0 (en) * 2020-07-16 2020-09-02 Ucl Business Ltd Gene therapy for neuromuscular and neuromotor disorders
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
US20230295656A1 (en) 2020-08-06 2023-09-21 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022072324A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Isl1 and lhx3 vector
US20240269322A1 (en) * 2020-10-21 2024-08-15 Chan Zuckerberg Biohub, Inc. Adeno-associated virus virions and methods of use thereof
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
MX2024004217A (es) 2021-10-08 2024-06-26 Dyno Therapeutics Inc Variantes de cápside y métodos de uso de estas.
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CA3272944A1 (en) 2022-12-29 2024-07-04 Voyager Therapeutics Inc MAPPING COMPOSITIONS AND REGULATION METHODS
WO2024226790A1 (en) * 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
TW202449167A (zh) 2023-04-26 2024-12-16 美商航海家醫療公司 用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法
WO2025122644A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755454B1 (en) * 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US20080318210A1 (en) * 2003-08-27 2008-12-25 Rosetta Genomics Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
WO2005017127A2 (en) * 2003-02-21 2005-02-24 The Penn State Research Foundation Rna interference compositions and methods
AU2004239114B2 (en) * 2003-05-14 2008-03-13 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
US20050064489A1 (en) * 2003-09-24 2005-03-24 Zhang Fang Liang Engineered U6 and H1 promoters
AU2005307737C1 (en) * 2004-11-18 2013-08-29 The Board Of Trustees Of The University Of Illinois Multicistronic siRNA constructs to inhibit tumors
WO2008134646A2 (en) * 2007-04-26 2008-11-06 University Of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
WO2010078536A1 (en) * 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2010140862A2 (ko) * 2009-06-05 2010-12-09 Seol Dai-Wu 단일 또는 멀티 표적 유전자를 억제하는 멀티-시스트로닉 shRNA 발현 카세트
DK3119797T3 (da) * 2014-03-18 2021-03-15 Univ Massachusetts Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
MX2017006216A (es) * 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
KR102584655B1 (ko) * 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease

Similar Documents

Publication Publication Date Title
JP2020518266A5 (enExample)
JP2019519218A5 (enExample)
JP2019519219A5 (enExample)
JP2025173511A (ja) Aavカプシドの指向性の再指示
JP2021502060A5 (enExample)
US9181544B2 (en) Therapeutic compounds
US20250161485A1 (en) Aav capsid variants and uses thereof
JP2024095717A5 (enExample)
JP7413256B2 (ja) 神経変性疾患の遺伝子治療
JP2017510298A5 (enExample)
JP2025102825A (ja) アデノ随伴ウイルスベクター変種
RU2020108189A (ru) Композиции и способы лечения бокового амиотрофического склероза (als)
JP2016528897A5 (enExample)
AU2023279090A1 (en) Aav capsid variants and uses thereof
RU2020113262A (ru) Модулирующие полинуклеотиды
JP2005501557A5 (enExample)
HRP20201200T1 (hr) OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK
US20250215453A1 (en) Aav capsid variants and uses thereof
WO2024011112A1 (en) Aav capsid variants and uses thereof
JP2019534025A (ja) 治療用オリゴヌクレオチドの捕捉および検出
AU2019344006A1 (en) Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome
US20220213482A1 (en) Targeting misspliced transcripts in genetic disorders
WO2023129496A9 (en) Rnas for complement inhibition
WO2025038430A1 (en) Aav capsid variants and uses thereof
CN101173275B (zh) 抑制sars冠状病毒m蛋白基因表达的小干扰rna及其编码基因与应用